Renaissance Technologies (RenTech)'s GALT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 147,900 shares of Galectin Therapeutics Inc. (GALT) worth $412,641, representing 0.00% of the portfolio. First purchased in 2018-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in GALT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 291,373 shares. Largest reduction occurred in Q3 2021, reducing 360,103 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Galectin Therapeutics (GALT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Galectin Therapeutics (GALT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +147,900 | New Buy | 147,900 | $2.79 |
| Q3 2022 | -27,700 | Sold Out | 0 | $0.00 |
| Q2 2022 | -174,318 | Reduce 86.29% | 27,700 | $1.30 |
| Q1 2022 | -13,382 | Reduce 6.21% | 202,018 | $1.61 |
| Q4 2021 | +205,304 | Add 2033.52% | 215,400 | $2.07 |
| Q3 2021 | -360,103 | Reduce 97.27% | 10,096 | $3.86 |
| Q2 2021 | +63,199 | Add 20.59% | 370,199 | $3.20 |
| Q1 2021 | +291,373 | Add 1864.55% | 307,000 | $2.17 |
| Q4 2020 | +15,627 | New Buy | 15,627 | $2.24 |
| Q2 2020 | -20,100 | Sold Out | 0 | $0.00 |
| Q1 2020 | -19,000 | Reduce 48.59% | 20,100 | $1.94 |
| Q4 2019 | +39,100 | New Buy | 39,100 | $2.86 |
| Q3 2019 | -34,732 | Sold Out | 0 | $0.00 |
| Q2 2019 | +34,732 | New Buy | 34,732 | $4.15 |
| Q3 2018 | -37,300 | Sold Out | 0 | $0.00 |
| Q2 2018 | +37,300 | New Buy | 37,300 | $6.35 |
Renaissance Technologies (RenTech)'s Galectin Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Galectin Therapeutics Inc. (GALT) in Q2 2018, acquiring 37,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Galectin Therapeutics Inc. (GALT) for 16 quarters since Q2 2018.
Renaissance Technologies (RenTech)'s largest addition to Galectin Therapeutics Inc. (GALT) was in Q1 2021, adding 307,000 shares worth $666,000.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 147,900 shares of Galectin Therapeutics Inc. (GALT), valued at approximately $412,641.
As of the Q1 2026 filing, Galectin Therapeutics Inc. (GALT) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Galectin Therapeutics Inc. (GALT) was 370,199 shares, as reported at the end of Q2 2021.